CN101939334B - C型肝炎病毒抗体 - Google Patents

C型肝炎病毒抗体 Download PDF

Info

Publication number
CN101939334B
CN101939334B CN200880125928.5A CN200880125928A CN101939334B CN 101939334 B CN101939334 B CN 101939334B CN 200880125928 A CN200880125928 A CN 200880125928A CN 101939334 B CN101939334 B CN 101939334B
Authority
CN
China
Prior art keywords
antibody
seq
antibodies
humanized
fab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880125928.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN101939334A (zh
Inventor
戴维·J·马修斯
戴维·G·威廉斯
阿尔文德·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aike Life
Original Assignee
Medical Research Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council Technology filed Critical Medical Research Council Technology
Publication of CN101939334A publication Critical patent/CN101939334A/zh
Application granted granted Critical
Publication of CN101939334B publication Critical patent/CN101939334B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
CN200880125928.5A 2007-12-17 2008-12-17 C型肝炎病毒抗体 Expired - Fee Related CN101939334B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US606607P 2007-12-17 2007-12-17
US61/006,066 2007-12-17
PCT/IB2008/003952 WO2009081285A2 (en) 2007-12-17 2008-12-17 Hepatitis c virus antibodies

Publications (2)

Publication Number Publication Date
CN101939334A CN101939334A (zh) 2011-01-05
CN101939334B true CN101939334B (zh) 2015-01-14

Family

ID=40801628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880125928.5A Expired - Fee Related CN101939334B (zh) 2007-12-17 2008-12-17 C型肝炎病毒抗体

Country Status (18)

Country Link
US (1) US9193781B2 (enExample)
EP (1) EP2231704B1 (enExample)
JP (1) JP5763344B2 (enExample)
KR (1) KR20100102163A (enExample)
CN (1) CN101939334B (enExample)
AR (1) AR072039A1 (enExample)
AU (1) AU2008341542B2 (enExample)
BR (1) BRPI0821252A2 (enExample)
CA (1) CA2708740C (enExample)
CL (1) CL2008003784A1 (enExample)
IL (1) IL205795A0 (enExample)
MX (1) MX2010006767A (enExample)
NZ (1) NZ585622A (enExample)
PE (1) PE20091109A1 (enExample)
RU (1) RU2462475C2 (enExample)
TW (1) TW200940090A (enExample)
WO (1) WO2009081285A2 (enExample)
ZA (1) ZA201003509B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
CA2584066C (en) 2004-10-07 2018-01-23 Transmedics, Inc. Systems and methods for ex-vivo organ care
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US9247728B2 (en) 2008-01-31 2016-02-02 Transmedics, Inc. Systems and methods for ex vivo lung care
AU2009335788A1 (en) * 2008-12-17 2011-07-07 Genentech, Inc. Hepatitis C virus combination therapy
NZ616699A (en) 2011-04-14 2016-03-31 Transmedics Inc Organ care solution for ex-vivo machine perfusion of donor lungs
EP2705150B1 (en) 2011-05-02 2020-07-29 The Johns Hopkins University A synthetic hepatitis c genome and methods of making and use
US20130084301A1 (en) * 2011-08-30 2013-04-04 Steven Foung Cluster of Neutralizing Antibodies to Hepatitis C Virus
US10215457B2 (en) * 2011-12-09 2019-02-26 Applied Materials, Inc. Heat exchanger for cooling a heating tube and method thereof
ITFI20120122A1 (it) * 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
CN102928595A (zh) * 2012-10-12 2013-02-13 武汉康苑生物医药科技有限公司 丙型肝炎病毒抗原抗体时间分辨免疫荧光分析法联合检测及检测试剂盒
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
US10751410B2 (en) * 2013-09-19 2020-08-25 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
EP3151663B1 (en) 2014-06-02 2020-09-23 Transmedics, Inc. Ex vivo organ care system
GB201415714D0 (en) 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
WO2016090498A1 (en) 2014-12-12 2016-06-16 Freed Darren Apparatus and method for organ perfusion
CN112933394B (zh) 2015-09-09 2023-10-24 特兰斯迈迪茨公司 用于在离体器官护理系统中使用的主动脉插管
CN105177017B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r4-85及其应用
CN105219780B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用
KR102640157B1 (ko) * 2016-03-22 2024-02-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 인간화 항-클라우딘-1 항체 및 이의 용도
DK3462861T5 (da) 2016-05-30 2024-01-08 Transmedics Inc Fremgangsmåde til ex vivo-lungeventilati on med et varierende udvendigt tryk
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1068335A (zh) * 1991-06-10 1993-01-27 吉祥有限公司 C型肝炎诊断制剂和疫苗
WO2006041866A2 (en) * 2004-10-05 2006-04-20 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
WO2006100449A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
CN1856508A (zh) * 2002-01-30 2006-11-01 罗伯托·布里奥尼 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPN960013A1 (it) * 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
EP1355947A2 (en) * 2000-12-01 2003-10-29 The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1068335A (zh) * 1991-06-10 1993-01-27 吉祥有限公司 C型肝炎诊断制剂和疫苗
CN1856508A (zh) * 2002-01-30 2006-11-01 罗伯托·布里奥尼 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段
WO2006041866A2 (en) * 2004-10-05 2006-04-20 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
WO2006100449A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Characterization of the Hepatitis C Virus E2 Epitope Defined by the Broadly Neutralizing Monoclonal Antibody AP33;Tarr AW等;《HEPATOLOGY》;20060222;第43卷(第3期);第592-600页 *

Also Published As

Publication number Publication date
JP2011505867A (ja) 2011-03-03
EP2231704B1 (en) 2015-08-12
CA2708740C (en) 2017-07-18
NZ585622A (en) 2012-10-26
US9193781B2 (en) 2015-11-24
CN101939334A (zh) 2011-01-05
RU2462475C2 (ru) 2012-09-27
US20110002926A1 (en) 2011-01-06
MX2010006767A (es) 2010-10-05
EP2231704A2 (en) 2010-09-29
JP5763344B2 (ja) 2015-08-12
HK1144440A1 (en) 2011-02-18
AU2008341542A1 (en) 2009-07-02
ZA201003509B (en) 2011-12-28
WO2009081285A2 (en) 2009-07-02
BRPI0821252A2 (pt) 2015-06-16
KR20100102163A (ko) 2010-09-20
AR072039A1 (es) 2010-08-04
RU2010129429A (ru) 2012-01-27
CL2008003784A1 (es) 2009-08-14
CA2708740A1 (en) 2009-07-02
PE20091109A1 (es) 2009-08-12
TW200940090A (en) 2009-10-01
WO2009081285A3 (en) 2010-08-26
IL205795A0 (en) 2010-11-30
AU2008341542B2 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
CN101939334B (zh) C型肝炎病毒抗体
CN106999566B (zh) 结合埃博拉病毒糖蛋白的抗体及其用途
AU2009207644A1 (en) Humanized anti-human NKG2A monoclonal antibody
CN104245731A (zh) 抗乙型流感病毒的广泛保护性人单克隆抗体及其使用方法
JP2010518854A (ja) Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
US20240247072A1 (en) Development and use of function-enhanced antibody blocking agent
CA3105415A1 (en) Antibodies specific to folate receptor alpha
KR20230034944A (ko) Abcb5에 특이적인 항체 및 그의 용도
JP2023052664A (ja) 抗配列類似性１９を持つファミリー、メンバーａ５抗体及びその使用方法
WO2021212021A2 (en) Coronavirus antibodies and methods of use thereof
US20120027722A1 (en) Hepatitis c virus combination therapy
US20170002097A1 (en) Multi-specific binding proteins
EP2481424A1 (en) Improvements in or relating to treatment and prevention of hepatitis C viral infections
CN118804927A (zh) 抗b7-h7抗体或其抗原结合片段及制备方法和应用
US20220332817A1 (en) Antibodies against human trem-1 and uses thereof
US20210147566A1 (en) Antibodies and uses thereof
HK1144440B (en) Hepatitis c virus antibodies
US20230391885A1 (en) Claudin 18.2 antibodies, methods of making the same, and uses thereof
CN120225558A (zh) 针对人程序性细胞死亡蛋白1(pd-1)的单克隆抗体
HK1184168A1 (zh) 拮抗性抗il-7受体抗体及方法
AU2012254920A1 (en) Improvements in or relating to treatment and prevention of viral infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: London, England

Patentee after: Aike life

Address before: London, England

Patentee before: Medical Res Council Technology

CP01 Change in the name or title of a patent holder
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20110105

Assignee: Shanghai xinshengyuan Pharmaceutical Group Co. Ltd.

Assignor: Aike life

Contract record no.: 2019990000088

Denomination of invention: Hepatitis c virus antibodies

Granted publication date: 20150114

License type: Exclusive License

Record date: 20190325

EE01 Entry into force of recordation of patent licensing contract
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150114

Termination date: 20201217

CF01 Termination of patent right due to non-payment of annual fee